argenx Announces Results of Extraordinary General Meeting of Shareholders
argenx (Euronext & Nasdaq: ARGX) announced the results of its Extraordinary General Meeting held on November 18, 2025 in Amsterdam.
The sole agenda item, the company’s remuneration policy, was approved by the required majority with 95.67% of votes in favor and 91.1% of share capital represented at the meeting. Voting results and all related meeting documents are available on the company’s investor website at www.argenx.com/investors/shareholder-meetings.
argenx (Euronext & Nasdaq: ARGX) ha annunciato i risultati della sua Assemblea Generale Straordinaria tenutasi il 18 novembre 2025 ad Amsterdam.
L'unico punto all'ordine del giorno, la policy di remunerazione della società, è stata approvata dalla maggioranza richiesta con 95,67% dei voti favorevoli e 91,1% del capitale sociale rappresentato all'incontro. I risultati delle votazioni e tutti i documenti relativi all'assemblea sono disponibili sul sito degli investitori della società all'indirizzo www.argenx.com/investors/shareholder-meetings.
argenx (Euronext y Nasdaq: ARGX) anunció los resultados de su Junta General Extraordinaria celebrada el 18 de noviembre de 2025 en Ámsterdam.
El único punto del orden del día, la política de remuneración de la empresa, fue aprobada por la mayoría requerida con 95,67% de votos a favor y 91,1% del capital social representado en la reunión. Los resultados de la votación y todos los documentos relacionados con la reunión están disponibles en la página web de inversores de la empresa en www.argenx.com/investors/shareholder-meetings.
argenx (Euronext & Nasdaq: ARGX)은 암스테르담에서 2025년 11월 18일에 열린 임시 일반 주주총회의 결과를 발표했습니다.
유일한 의제인 회사의 보상 정책은 필요한 다수의 찬성을 얻어 95.67%의 찬성표와 회의에 대표된 주식 자본의 91.1%를 얻어 승인되었습니다. 투표 결과 및 회의 관련 모든 문서는 회사의 투자자 웹사이트 www.argenx.com/investors/shareholder-meetings에서 확인할 수 있습니다.
argenx (Euronext et Nasdaq : ARGX) a annoncé les résultats de son Assemblée générale extraordinaire tenue le 18 novembre 2025 à Amsterdam.
Le seul point à l'ordre du jour, la politique de rémunération de l'entreprise, a été approuvé par la majorité requise avec 95,67% des voix pour et 91,1% du capital social représenté lors de la réunion.
Les résultats des votes et tous les documents relatifs à la réunion sont disponibles sur le site web des investisseurs de l'entreprise à l'adresse www.argenx.com/investors/shareholder-meetings.
argenx (Börse Euronext & Nasdaq: ARGX) gab die Ergebnisse der außerordentlichen Hauptversammlung bekannt, die am 18. November 2025 in Amsterdam stattfand.
Der einzige Antragspunkt, die Vergütungspolitik des Unternehmens, wurde von der erforderlichen Mehrheit mit 95,67% der Stimmen und 91,1% des am Treffen vertretenen Aktienkapitals angenommen.
Die Abstimmungsergebnisse und alle damit verbundenen Sitzungsdokumente sind auf der Investoren-Website des Unternehmens unter www.argenx.com/investors/shareholder-meetings verfügbar.
argenx (بورصة يورونيكس ونزدك: ARGX) أعلنت نتائج اجتماع الجمعية العامة غير العادية الذي عُقد في 18 نوفمبر 2025 في أمستردام.
البند الوحيد في جدول الأعمال، سياسة التعويض للشركة، تم اعتماده بموجب الأغلبية المطلوبة بنسبة 95.67% من الأصوات المؤيدة و< b>91.1% من رأس المال الممثل في الاجتماع.
نتائج التصويت وجميع الوثائق المتعلقة بالاجتماع متاحة على موقع المستثمرين للشركة على www.argenx.com/investors/shareholder-meetings.
- None.
- None.
November 18, 2025 – 10:01 PM CET
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025.
The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company’s remuneration policy was approved by a
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx
website at www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
What did argenx shareholders vote on at the November 18, 2025 EGM (ARGX)?
What percentage voted in favor of argenx’s remuneration policy at the November 18, 2025 EGM (ARGX)?
How much share capital was represented at argenx’s November 18, 2025 EGM (ARGX)?
Where can I find the full voting results and documents from argenx’s November 18, 2025 EGM (ARGX)?
Does the approval of the remuneration policy on November 18, 2025 change argenx’s executive pay immediately (ARGX)?
